Evidence map›Paper›PMID 42266404›Full record

ArticleJournal of asthma and allergy2026

Dupilumab is Effective in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.

Mark Boguniewicz, Lawrence D Sher, Amy S Paller, Peter D Arkwright, Shigemi Yoshihara, Wendy Smith Begolka, Zhen Chen, Parul Shah, Ainara Rodríguez Marco

Registry-linked trialAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03346434 (A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03346434 phase2 / phase3completednot on this map

A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2017 to 2021Enrolled202ConditionsDermatitis, AtopicArmsDupilumab, Matching placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mark BoguniewiczDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Lawrence D SherPeninsula Research Associates, Rolling Hills Estates, CA, USA.
Amy S PallerDepartments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID 0000-0001-6187-6549
Peter D ArkwrightLydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.
Shigemi YoshiharaDepartment of Pediatrics, School of Medicine, Dokkyo Medical University, Tochigi, Japan.
Wendy Smith BegolkaNational Eczema Association, Novato, CA, USA.
Zhen ChenDepartment of Pediatrics, School of Medicine, Dokkyo Medical University, Tochigi, Japan.
Parul ShahRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.ORCID 0009-0000-3656-5925
Ainara Rodríguez MarcoSanofi, Madrid, Spain.ORCID 0009-0002-3021-6454

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is this summary about?: This is a summary of a post hoc study of the LIBERTY AD PRESCHOOL trial published in October 2024. The trial included 162 infants and children aged 6 months to 5 years who had moderate-to-severe atopic dermatitis (AD). Researchers showed that an injectable drug called dupilumab resulted in improved AD, whether or not patients also had asthma, allergic rhinitis (nasal allergy), or food allergy, diseases that are closely related to AD. What are the key takeaways?: We found that dupilumab improved AD in the infants and children, whether or not they also had one of the other related diseases. What were the main conclusions reported by the researchers?: Dupilumab works well to treat infants and children with AD, even if they also have asthma, allergic rhinitis, or food allergy. Dupilumab was well tolerated and overall safety was consistent with the known dupilumab safety profile. Clinical trial number: : NCT03346434.

Indexed as

Allergic rhinitisAsthmaAtopic dermatitisDupilumab

Identifiers

PMID42266404
PMCPMC13244477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.